ArticleFrontiers in cardiovascular medicine2025
Lifelong TMAO exposure exerts hypotensive effects in aged spontaneously hypertensive rats.
Article in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Trimethylamine N-oxide in exercise physiology: a gut microbiota-derived signal linking metabolic stress, redox balance and cardiometabolic health.European journal of applied physiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Trimethylamine N-oxide (TMAO), a bacterial metabolite associated with cardiovascular risk, has a debated role, with evidence suggesting both harmful and protective effects. We hypothesized that chronic TMAO supplementation modulates hypertension-related complications through alterations in the tissue renin-angiotensin system (RAS). Ten-week-old male spontaneously hypertensive rats (SHRs) were divided into two groups, receiving either water or TMAO-supplemented water for 80 weeks. Circulatory parameters, including hemodynamics, echocardiographic measurements, and pathomorphological assessments, tissue RAS expression and biomarker profiles, were evaluated. Rats treated with TMAO exhibited significantly higher plasma TMAO levels accompanied by significantly lower mean and systolic blood pressure and NT-proBNP levels. In the TMAO group, diuresis and natriuresis were numerically increased, and the left atrial size was smaller. No pathological effects of TMAO on the circulatory system were observed in rats. Echocardiographic parameters and age-related histopathological changes, including fibrosis in the heart and kidneys, were comparable between groups. TMAO-treated rats showed upregulated expression of RAS components, including angiotensinogen and AT1b and AT2 receptors, in the heart, kidneys, and colon. TMAO supplementation also increased blood and urinary levels of trimethylamine, a toxic precursor and metabolite of TMAO. In conclusion, lifelong exposure to TMAO improves circulatory function in hypertension, as evidenced by reduced blood pressure, lower NT-proBNP levels, and decreased left atrial size-findings consistent with a reduction in cardiac workload. The upregulation of RAS components may represent a compensatory response to the blood pressure-lowering effect of TMAO. However, the concurrent rise in potentially toxic TMA levels warrants further investigation to fully assess the long-term safety of TMAO supplementation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.